In vitro comparison of the complement-scavenging capacity of different intravenous immunoglobulin preparations

• Published in: Vox sanguinis 2009-11, Vol.97 (4), p.348-354
• Main Authors: Spycher, M., Matozan, K., Minnig, K., Zehnder, R., Miescher, S., Hoefferer, L., Rieben, R.
• Format: Article
• Language: English
• Subjects: Autoimmune diseases; Biochemistry; Blood; Complement Activation; Complement C3a - chemistry; Complement C3a - immunology; Complement C5a - analysis; Complement C5a - immunology; Complement Fixation Tests - methods; complement inhibition; complement scavenging; Dose-Response Relationship, Immunologic; Humans; Immunoglobulins; Immunoglobulins, Intravenous - analysis; Immunoglobulins, Intravenous - immunology; Inflammatory diseases; intravenous immunoglobulin; IVIG
• ISSN: 0042-9007; 1423-0410
• DOI: 10.1111/j.1423-0410.2009.01217.x

Background and Objectives  Complement inhibition is considered important in the mechanism of action of intravenous immunoglobulin (IVIG) in a number of inflammatory and autoimmune disorders. The capacity of different IVIG preparations to ‘scavenge’ activated C3 and thereby inhibit complement activation was assessed by a new in vitro assay. Materials and Methods  Diluted human serum as a complement source, with or without addition of different concentrations of IVIG, was incubated in microtitre plates coated with heat‐aggregated human IgG. Complement scavenging was measured by detecting reduced C3 binding and determining fluid phase C3b–IgG complex formation. Complement activation induced by the IVIG preparations was measured as C5a formation. Results  All IVIG preparations exhibited a dose‐dependent inhibition of C3b deposition, correlating strongly with binding of C3b to fluid‐phase IgG, but the extent of complement scavenging varied considerably between different IVIG preparations. At an IVIG concentration of 0·9 mg/ml, the inhibition of C3b deposition ranged from 72 ± 16% to 22 ± 4·1%. The reduction of C3b deposition on the complement‐activating surface was not due to IVIG‐induced complement activation in the fluid phase, as shown by the low C5a formation in the presence of serum. Conclusion  In vitro analysis allows comparison of the complement‐inhibitory properties of IVIG preparations. The extent of complement scavenging varies between the products.